| Unique ID issued by UMIN | UMIN000054368 |
|---|---|
| Receipt number | R000062095 |
| Scientific Title | A study to evaluate the effect of the test food intake on stress |
| Date of disclosure of the study information | 2024/05/10 |
| Last modified on | 2025/02/03 09:08:20 |
A study to evaluate the effect of the test food intake on stress
A study to evaluate the effect of the test food intake on stress
A study to evaluate the effect of the test food intake on stress
A study to evaluate the effect of the test food intake on stress
| Japan |
Healthy subjects
| Adult |
Others
NO
To evaluate the effect of the test food intake on stress in healthy Japanese men and women
Safety,Efficacy
State-Trait Anxiety Inventory
(Secondary outcomes)
Visual Analog Scale, salivary test (cortisol), heart rate variability (LF/HF)
(Safety evaluation)
Vital signs, physical measurements (body weight and BMI), biochemical test, hematology test, urinalysis, adverse events
Interventional
Cross-over
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Prevention
| Food |
Test food intake for 4 weeks
Washout (28 days or more )
Placebo food intake for 4 weeks
Placebo food intake for 4 weeks
Washout (28 days or more )
Test food intake for 4 weeks
| 20 | years-old | <= |
| 60 | years-old | >= |
Male and Female
1.Japanese males and females who are between 20 and 60 years of age at the time of written informed consent.
2.Subjects who are aware of stress on a daily basis.
3.Subjects with the Beck Depression Inventory-II (BDI-II) score of < 20.
4.Subjects who are systolic blood pressure between 101 mmHg and 139 mmHg, and diastolic blood pressure between 61 mmHg and 89 mmHg.
5.Subjects who have a regular or part-time job.
6.Subjects who are fully explained the purpose and details of the study, have ability to consent, are volunteering to participate in the study with a full understanding of the explanation, and have consented to participate in the study in writing.
1.Subjects receiving medication or outpatient treatment for a serious disease.
2.Subjects receiving exercise or diet therapy under the supervision of a physician.
3.Subjects who may develop an allergy to the ingredient of the test food (rosemary) or aspirin.
4.Subjects with current or previous history of drug dependence or alcohol dependence.
5.Subjects who are currently seeing a doctor for the treatment of a psychiatric disorder (e.g., depression) and/or sleep disorder (e.g., insomnia, sleep apnea syndrome) or have previous history of a psychiatric disorder.
6.Subjects who have extremely irregular life rhythms due to night work, shift work, etc.
7.Subjects whose eating, sleeping, and other habits are extremely irregular.
8.Subjects who are having a very unbalanced diet.
9.Heavy users of alcohol (the mean consumption of pure alcohol is 60 g/day or more) or excessive smokers (21 cigarettes/day or more).
10.Subjects with current or previous history of a brain disease, malignancy, immunological disease, diabetes mellitus, hepatic disease (hepatitis), renal disease, cardiac disease, thyroid disease, adrenal disease, metabolic disease, or other serious diseases.
11.Subjects who use or are unable to stop using health foods, supplements (e.g., GABA, rosemary, caffeine, and theanine), and drugs that may affect stress.
12.Subjects who regularly drink energy drinks.
13.Subjects who anticipate a major change or stressful situation in their home or working environment (e.g., job change, move, marriage) from one month before screening to study completion.
14.Subjects who participated in another clinical study/research within 3 months before the date of informed consent or who plan to participate in another clinical study/research during the study period.
15.Subjects who donated more than 200 mL of whole blood, plasma, or platelets within 1 month before the date of informed consent or 400 mL within 3 months before the date of informed consent.
40
| 1st name | Satoshi |
| Middle name | |
| Last name | Fukumitsu |
NIPPN CORPORATION
Innovation Center, Central Research Laboratory
243-0041
5-1-3 Midorigaoka Atsugi Kanagawa 243-0041, Japan
046-222-6963
sfukumitsu@nippn.co.jp
| 1st name | Hiroyuki |
| Middle name | |
| Last name | Miyazawa |
HUMA R&D CORP
Clinical Development Department
108-0023
NAKANO SPRING Bld 5F, 4-11-17 Shibaura, Minato-ku, Tokyo 108-0023 Japan
03-3431-1260
rd@huma-rd.co.jp
HUMA R&D CORP
NIPPN CORPORATION
Profit organization
AMC Shinjuku Clinic Ethics Committee
5F,SIL Shinjuku-building ,2-46-3,Kabukicho,Shinju-ku,Tokyo,160-0021,Japan
03-6709-6071
amcshinjuku@amc-clinic.jp
NO
| 2024 | Year | 05 | Month | 10 | Day |
Unpublished
40
Completed
| 2024 | Year | 04 | Month | 04 | Day |
| 2024 | Year | 04 | Month | 12 | Day |
| 2024 | Year | 05 | Month | 13 | Day |
| 2024 | Year | 09 | Month | 27 | Day |
| 2024 | Year | 10 | Month | 21 | Day |
| 2024 | Year | 10 | Month | 24 | Day |
| 2025 | Year | 01 | Month | 28 | Day |
(Exclusion criteria continued)
16.Subjects who are currently pregnant or lactating, may become pregnant during the study period, or are planning to become pregnant during the study period.
17.Subjects who have difficulty complying with recording of each survey form.
18.Subjects whose laboratory test values or measurements at screening indicate their ineligibility to participate in the study.
19.Other Subjects who are considered ineligible for participation in the study by the investigator.
| 2024 | Year | 05 | Month | 10 | Day |
| 2025 | Year | 02 | Month | 03 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000062095